AM-Pharma is a biopharmaceutical company focused on developing innovative therapeutics for acute kidney injury (AKI) and sepsis-associated conditions. The company operates in the healthcare and biotechnology market, targeting hospitals and medical research institutions as its primary clients. AM-Pharma's core product is recombinant human Alkaline Phosphatase (recAP), which is currently undergoing Phase III clinical trials. The business model revolves around the research, development, and eventual commercialization of recAP, with funding sourced from venture capital, grants, and partnerships. Revenue generation is anticipated through the successful approval and sale of recAP, as well as potential licensing agreements and collaborations with larger pharmaceutical companies.

Keywords: biopharmaceutical, acute kidney injury, sepsis, Alkaline Phosphatase, recAP, Phase III trials, healthcare, biotechnology, therapeutics, commercialization.